FDA Approves Ketamine Nasal Spray as First and Only Standalone Therapy for Treatment-Resistant Depression
Veriheal
JUNE 12, 2025
With the FDA approval of the brand-name Spravato nasal spray as a standalone therapy for individuals with TRD, patients can now obtain a prescription to be treated in a clinical setting with a nasal spray containing a kind of ketamine molecule called esketamine (as in the “S form” of the ketamine molecule— S -ketamine).
Let's personalize your content